A vaccine trial for the coronavirus by joint team of Oxford University researchers and pharmaceutical company, AstraZeneca Plc has shown strong immune response in early testings with humans. Lifting AstraZeneca shares as high as 10% in London today as a possible vaccine may come in the near future.
The report revealed that the trials showed protective neutralization of antibodies and immune t-cells aimed at the virus. Oxford’s Chief of Jenner Institute, Adrian Hill, said the research has recorded good immune system responses.
This also comes as another Biotech firm; Moderna Inc announced last week that its potential vaccine recorded higher levels of antibody research against the coronavirus.
Mr Hill also announced that it would be a necessary advantage if other companies and research groups report on vaccines, which will enable the world have more vaccines. This comes at a time when as much as 160 companies and groups globally are researching on a potential vaccine. However, the Oxford-AstraZeneca group seems to be far ahead of everyone as their vaccine reaches final stage of testing.
READ MORE: COVID-19: WHO stops hydroxychloroquine, HIV drugs trial after failure
AstraZeneca also announced that it can begin production of doses across the UK by September. Results from the group’s test with animals showed the vaccine was a catalyst for an immune response.
The US government has already pledged $1.2 billion towards the development of a potential vaccine with AstraZeneca, which would enable the United States government receive supplies by October.
The research revealed that surface spike protein from the virus was infused with genetic material, which tricks the immune system into fighting back, stimulating antibodies and white blood t-cells that help the immune system fight infections.
